FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare
Syndicate content

Eisai related Press Releases

Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil

Posted March 9, 2009

Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil SAN JOSE, Calif., March 9 /PRNewswire/ -- Teikoku Pharma USA Inc., the... Read more...

FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

Posted December 14, 2008

WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium)... Read more...

FDA Approves BANZEL(TM) (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder

Posted November 15, 2008

FDA Approves BANZEL(TM) (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder New Treatment Option for Seizures Associated with Lennox-Gastaut Syndrome WOODCLIFF LAKE, N.J., Nov. 14... Read more...

TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai

Posted November 10, 2008

TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai

LA JOLLA, CA, November 10, 2008 - TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has agreed to

... Read more...

Morphotek, Inc. and Pivotal BioSciences Announce Agreement for the Development of Therapeutic Monoclonal Antibodies

Posted September 25, 2008

Morphotek, Inc. and Pivotal BioSciences Announce Agreement for the Development of Therapeutic Monoclonal Antibodies EXTON, Pa.--(BUSINESS... Read more...

Status of the E2007 Development Program

Posted April 11, 2008

Status of the E2007 Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications Friday April 11 TOKYO, Japan, April 11 --... Read more...

PRESS RELEASE: EISAI TO ACQUIRE MGI PHARMA FOR $41 PER SHARE IN AN ALL CASH TRANSACTION

Posted December 10, 2007

EISAI TO ACQUIRE MGI PHARMA FOR $41 PER SHARE IN AN ALL CASH TRANSACTION Tokyo, Japan, and Bloomington, MN, December 10, 2007 - Eisai Co., Ltd. (TSE: 4523.JP) ("Eisai"), a research-based... Read more...